Fully automated flow cytometry

Beckman Coulter’s new, automated Aquios CL flow cytometer has received clearance from the US Food and Drug Administration (FDA) for use in the clinical laboratory.The small-footprint, high-precision instrument has been designed specifically for the Lean laboratory, operating 24/7 and requiring automated systems which improve workflow, enhance quality and deliver a consistent turnaround time (TAT).

Easy to operate with integrated automated sample preparation, the Aquios CL flow cytometerdelivers first results within 20 minutes for routine applications such as immunophenotyping.Subsequent results are available at a rate of 25 samples per hour for up to a full 96-well plate.Once samples are loaded, the instrument automatically carries out mixing, cap piercing, sample preparation and analysis.Its automated cap-piercing technology helps to reduce staff exposure to biohazardous samples. 

The fully integrated system includes a 40-tube capacity autoloader able to handle various tube sizes, with continuous, random loading and unloading. There is a separate single-tube loader for STAT samples.Sample preparation, reagent monitoring, barcode scanning and LIS connectivityare all automated.Intuitive software also makes the system fast and easy to use.SmartTrack reagent monitoring tracks reagent use and test progress, with barcode tracking eliminating manual quality control and reagent logs.If the QC fails, the system automatically alerts the operator by text message or email.


Other news

Upcoming Events


Technological University Dublin
3-4 September 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Lab Innovations

NEC, Birmingham (Hall 12)
30 & 31 October 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Jun 2019

Recent advances in cancer diagnostics

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.